EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access

Second-dose intravenous thrombolysis with tenecteplase in alteplase-resistant medium-vessel-occlusion strokes: A retrospective and comparative study

Nicolas Chausson, Stéphane Olindo, François-Xavier Laborne, Manvel Aghasaryan, Pauline Renou, Djibril Soumah, Sabrina Debruxelles, Tony Altarcha, Mathilde Poli, Yann L'Hermitte, Sharmila Sagnier, Moussa Toudou-Daouda und 10 weitere

European Stroke Journal · 01.12.2024 · 9 (4) · 943-951

DOI: 10.1177/23969873241254936 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Stroke Journal, online erschienen am 01.12.2024. Verfasst von Nicolas Chausson und 21 weiteren Autor:innen. Beteiligte Einrichtung: Unité Neuro-vasculaire, Hôpital Sud-Francilien, Corbeil-Essonnes, France. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Tenecteplase, Thrombolytic Therapy, Tissue Plasminogen Activator. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In intracranial medium-vessel occlusions (MeVOs), intravenous thrombolysis (IVT) shows inconsistent effectiveness and endovascular interventions remains unproven. We evaluated a new therapeutic strategy based on a second IVT using tenecteplase for MeVOs without early recanalization post-alteplase. Patients and methods: This retrospective, comparative study included consecutively low bleeding risk MeVO patients treated with alteplase 0.9 mg/kg at two stroke centers. One center used a conventional single-IVT approach; the other applied a dual-IVT strategy, incorporating a 1-h post-alteplase MRI and additional tenecteplase, 0.25 mg/kg, if occlusion persisted. Primary outcomes were 24-h successful recanalization for efficacy and symptomatic intracranial hemorrhage (sICH) for safety. Secondary outcomes included 3-month excellent outcomes (modified Rankin Scale score of 0–1). Comparisons were conducted in the overall cohort and a propensity score-matched subgroup.

Results

Among 146 patients in the dual-IVT group, 103 failed to achieve recanalization at 1 h and of these 96 met all eligible criteria and received additional tenecteplase. Successful recanalization at 24 h was higher in the 146 dual-IVT cohort patients than in the 148 single-IVT cohort patients (84% vs 61%, p < 0.0001), with similar sICH rate (3 vs 2, p = 0.68). Dual-IVT strategy was an independent predictor of 24-h successful recanalization (OR, 2.7 [95% CI, 1.52–4.88]; p < 0.001). Dual-IVT cohort patients achieved higher rates of excellent outcome (69% vs 44%, p < 0.0001). Propensity score matching analyses supported all these associations.

Conclusion

In this retrospective study, a dual-IVT strategy in selected MeVO patients was associated with higher odds of 24-h recanalization, with no safety concerns. However, potential center-level confounding and biases seriously limit these findings’ interpretation. Trial Registration ClinicalTrials.gov Identifier: NCT05809921

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, IntravenousIschemic StrokeRetrospective StudiesStrokeTreatment Outcome

Stichwörter der Autor:innen

Acute strokemedium-vessel occlusiontenecteplasethrombolysis

Substanzen

Fibrinolytic AgentsTenecteplaseTissue Plasminogen Activator

Autor:innen und Institutionen

  • Unité Neuro-vasculaire, Hôpital Sud-Francilien, Corbeil-Essonnes, France.
  • INSERM U1266, Paris, France.
  • Unité Neuro-vasculaire, CHU de Bordeaux, Bordeaux, France.
  • Unité de Recherche Clinique, Hôpital Sud Francilien, Corbeil-Essonnes, France.

ORCID-Profile: Didier Smadja

Zitieren

APA

Chausson, N., Olindo, S., Laborne, F. X., Aghasaryan, M., Renou, P., Soumah, D., Debruxelles, S., Altarcha, T., Poli, M., L'Hermitte, Y., Sagnier, S., Toudou-Daouda, M., Aminou-Tassiou, N. R., Bentamra, L., Benmoussa, N., Alecu, C., Imbernon, C., Smadja, L., Ouanounou, G., …, & Smadja, D. (2024). Second-dose intravenous thrombolysis with tenecteplase in alteplase-resistant medium-vessel-occlusion strokes: A retrospective and comparative study. European Stroke Journal, 9(4), 943-951. https://doi.org/10.1177/23969873241254936

Vancouver

Chausson N, Olindo S, Laborne FX, Aghasaryan M, Renou P, Soumah D, et al. Second-dose intravenous thrombolysis with tenecteplase in alteplase-resistant medium-vessel-occlusion strokes: A retrospective and comparative study. European Stroke Journal. 2024;9(4):943-951. doi:10.1177/23969873241254936

BibTeX
@article{Chausson2024,
  author = {Chausson, Nicolas and Olindo, Stéphane and Laborne, François-Xavier and Aghasaryan, Manvel and Renou, Pauline and Soumah, Djibril and Debruxelles, Sabrina and Altarcha, Tony and Poli, Mathilde and L'Hermitte, Yann and Sagnier, Sharmila and Toudou-Daouda, Moussa and Aminou-Tassiou, Nana Rahamatou and Bentamra, Leila and Benmoussa, Narimane and Alecu, Cosmin and Imbernon, Carole and Smadja, Léonard and Ouanounou, Gary and Rouanet, François and Sibon, Igor and Smadja, Didier},
  title = {Second-dose intravenous thrombolysis with tenecteplase in alteplase-resistant medium-vessel-occlusion strokes: A retrospective and comparative study},
  journal = {European Stroke Journal},
  year = {2024},
  volume = {9},
  number = {4},
  pages = {943--951},
  doi = {10.1177/23969873241254936}
}
Kostenlos starten →